ENTPD1 and colorectal carcinoma: Thus, our results indicate that CD39+ Treg may be a superior immunosuppressive population compared to CD39− Treg and suggest that therapies aimed at reducing CD39+ Treg activity may be useful to reduce immunosuppression in CRC.